Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 70 Years or Older

Next Previous
Trial Profile

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 70 Years or Older

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2018

At a glance

  • Drugs GSK 1437173A (Primary)
  • Indications Herpes zoster; Postherpetic neuralgia; Varicella zoster virus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms ZOE-70
  • Sponsors GlaxoSmithKline

    • Most Recent Events

    • 23 Mar 2018 According to a GlaxoSmithKline media release, European Commission and the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Shingrix for the prevention of shingles (herpes zoster) and post-herpetic neuralgia (PHN), the most common and often painful shingles-related complication, in adults aged 50 years or older.
    • 26 Feb 2018 Results of pooled data from two trials (NCT01165177 and NCT01165229), were published in the Journal of Infectious Diseases.
    • 26 Jan 2018 According to a GlaxoSmithKline media release, European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for Shingrix for the prevention of shingles (herpes zoster) and post-herpetic neuralgia (PHN), the most common and often painful shingles-related complication, in adults aged 50 years or older.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top